Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCVJ86)

Drug Name
Clofarabine Drug Info
Synonyms
CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
119182
ChEBI ID
CHEMBL1750
CAS Number
CAS 123318-82-1
TTD Drug ID
D0R5RR
VARIDT Drug ID
DR01330
INTEDE Drug ID
DR1773

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
p53 signaling pathway 2.54 0.00e+0 63/73 (86.3%) CDKN1A;DDB2;FAS;...
NF-kappa B signaling pathway 2.18 0.00e+0 90/104 (86.54%) GADD45A;CXCL2;PTGS2;...
TNF signaling pathway 2.17 0.00e+0 103/112 (91.96%) FAS;CXCL2;PTGS2;...
Malaria 2.10 0.00e+0 44/50 (88%) CXCL8;SDC1;IL18;...
Rheumatoid arthritis 2.09 0.00e+0 78/93 (83.87%) CXCL2;CXCL8;ATP6V1D;...
Small cell lung cancer 2.09 0.00e+0 90/92 (97.83%) CDKN1A;DDB2;GADD45A;...
IL-17 signaling pathway 2.00 0.00e+0 84/94 (89.36%) CXCL2;PTGS2;FOSB;...
Epstein-Barr virus infection 2.00 1.36e-3 189/202 (93.56%) CDKN1A;DDB2;FAS;...
Pyrimidine metabolism 1.91 4.83e-3 40/56 (71.43%) RRM2;UPP1;TYMS;...
Graft-versus-host disease 1.89 5.43e-3 32/42 (76.19%) FAS;HLA-B;IL1A;...
Colorectal cancer 1.88 5.92e-3 84/86 (97.67%) CDKN1A;AREG;DDB2;...
Staphylococcus aureus infection 1.88 5.43e-3 72/95 (75.79%) KRT14;KRT17;KRT13;...
DNA replication 1.87 5.85e-3 34/36 (94.44%) RFC2;POLD4;LIG1;...
Type I diabetes mellitus 1.81 1.32e-2 38/43 (88.37%) FAS;HLA-B;IL1A;...
Thyroid cancer 1.80 1.23e-2 36/37 (97.3%) CDKN1A;DDB2;GADD45A;...
Allograft rejection 1.79 1.22e-2 32/38 (84.21%) FAS;HLA-B;HLA-A;...
Nucleotide excision repair 1.78 1.41e-2 40/47 (85.11%) DDB2;RFC2;POLD4;...
Cytokine-cytokine receptor interaction 1.77 1.33e-2 246/295 (83.39%) FAS;TNFRSF10B;CXCL2;...
Complement and coagulation cascades 1.74 1.71e-2 76/85 (89.41%) PLAT;CD55;F3;...
Apoptosis 1.74 2.01e-2 126/168 (75%) FAS;TNFRSF10B;PMAIP1;...
Influenza A 1.74 2.02e-2 156/172 (90.7%) FAS;TNFRSF10B;CXCL8;...
Pancreatic cancer 1.72 2.27e-2 75/76 (98.68%) CDKN1A;DDB2;GADD45A;...
Glutathione metabolism 1.72 2.27e-2 43/57 (75.44%) GSTM3;GPX3;RRM2;...
Synthesis and degradation of ketone bodies 1.71 2.31e-2 9/10 (90%) BDH1;ACAT1;BDH2;...
Glioma 1.71 2.26e-2 67/75 (89.33%) CDKN1A;DDB2;GADD45A;...
Viral protein interaction with cytokine and cytokine re... 1.70 2.51e-2 84/100 (84%) TNFRSF10B;CXCL2;CXCL8;...
Measles 1.69 2.64e-2 133/139 (95.68%) FAS;TNFAIP3;MX1;...
Melanoma 1.69 2.55e-2 68/72 (94.44%) CDKN1A;DDB2;GADD45A;...
Epithelial cell signaling in Helicobacter pylori infect... 1.67 2.60e-2 62/70 (88.57%) CXCL2;CXCL8;HBEGF;...
C-type lectin receptor signaling pathway 1.67 2.56e-2 93/104 (89.42%) PTGS2;RELB;EGR3;...
mRNA surveillance pathway -1.83 8.41e-3 71/98 (72.45%) NXF3;ACIN1;CSTF3;...
Nicotine addiction -1.83 1.05e-2 32/40 (80%) GRIA3;CACNA1A;SLC17A7;...
Aminoacyl-tRNA biosynthesis -1.91 2.80e-3 15/66 (22.73%) FARSA;GATC;TARS2;...
Spliceosome -2.14 0.00e+0 101/150 (67.33%) SNRNP40;CHERP;ACIN1;...
RNA transport -2.23 0.00e+0 128/186 (68.82%) ELAC2;NUP98;NXF3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H